Stem Cell And Regenerative Therapy Market 2019-2024 Chain Analysis, Upstream Raw Materials Sourcing and Downstream Buyers – Feed Road

The global stem cell and regenerative medicines market should grow from $21.8 billion in 2019 to reach $55.0 billion by 2024 at a compound annual growth rate (CAGR) of 20.4% for the period of 2019-2024.

Report Scope:

The scope of this report is broad and covers various type of product available in the stem cell and regenerative medicines market and potential application sectors across various industries. The current report offers a detailed analysis of the stem cell and regenerative medicines market.

Request For Report Sample:https://www.trendsmarketresearch.com/report/sample/11723

The report highlights the current and future market potential of stem cell and regenerative medicines and provides a detailed analysis of the competitive environment, recent development, merger and acquisition, drivers, restraints, and technology background in the market. The report also covers market projections through 2024.

The report details market shares of stem cell and regenerative medicines based on products, application, and geography. Based on product the market is segmented into therapeutic products, cell banking, tools and reagents. The therapeutics products segments include cell therapy, tissue engineering and gene therapy. By application, the market is segmented into oncology, cardiovascular disorders, dermatology, orthopedic applications, central nervous system disorders, diabetes, others

The market is segmented by geography into the following regions: North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report presents detailed analyses of major countries such as the U.S., Canada, Mexico, Germany, the U.K. France, Japan, China and India. For market estimates, data is provided for 2018 as the base year, with forecasts for 2019 through 2024. Estimated values are based on product manufacturers total revenues. Projected and forecasted revenue values are in constant U.S. dollars, unadjusted for inflation.

Report Includes:

28 data tables An overview of global markets for stem cell and regenerative medicines Analyses of global market trends, with data from 2018, estimates for 2019, and projections of compound annual growth rates (CAGRs) through 2024 Details of historic background and description of embryonic and adult stem cells Information on stem cell banking and stem cell research A look at the growing research & development activities in regenerative medicine Coverage of ethical issues in stem cell research & regulatory constraints on biopharmaceuticals Comprehensive company profiles of key players in the market, including Aldagen Inc., Caladrius Biosciences Inc., Daiichi Sankyo Co. Ltd., Gamida Cell Ltd. and Novartis AG

Summary

The global market for stem cell and regenerative medicines was valued at REDACTED billion in 2018. The market is expected to grow at a compound annual growth rate (CAGR) of REDACTED to reach approximately REDACTED billion by 2024. Growth of the global market is attributed to the factors such as growingprevalence of cancer, technological advancement in product, growing adoption of novel therapeuticssuch as cell therapy, gene therapy in treatment of chronic diseases and increasing investment fromprivate players in cell-based therapies.

To Get Discount:https://www.trendsmarketresearch.com/report/discount/11723

In the global market, North America held the highest market share in 2018. The Asia-Pacific region is anticipated to grow at the highest CAGR during the forecast period. The growing government funding for regenerative medicines in research institutes along with the growing number of clinical trials based on cell-based therapy and investment in R&D activities is expected to supplement the growth of the stem cell and regenerative market in Asia-Pacific region during the forecast period.

Reasons for Doing This Study

Global stem cell and regenerative medicines market comprises of various products for novel therapeutics that are adopted across various applications. New advancement and product launches have influenced the stem cell and regenerative medicines market and it is expected to grow in the near future. The biopharmaceutical companies are investing significantly in cell-based therapeutics. The government organizations are funding research and development activities related to stem cell research. These factors are impacting the stem cell and regenerative medicines market positively and augmenting the demand of stem cell and regenerative therapy among different application segments. The market is impacted through adoption of stem cell therapy. The key players in the market are investing in development of innovative products. The stem cell therapy market is likely to grow during the forecast period owing to growing investment from private companies, increasing in regulatory approval of stem cell-based therapeutics for treatment of chronic diseases and growth in commercial applications of regenerative medicine.

Products based on stem cells do not yet form an established market, but unlike some other potential applications of bioscience, stem cell technology has already produced many significant products in important therapeutic areas. The potential scope of the stem cell market is now becoming clear, and it is appropriate to review the technology, see its current practical applications, evaluate the participating companies and look to its future.

The report provides the reader with a background on stem cell and regenerative therapy, analyzes the current factors influencing the market, provides decision-makers the tools that inform decisions about expansion and penetration in this market.

Make an Inquiry before [emailprotected]https://www.trendsmarketresearch.com/checkout/11723/Single

Read the original here:
Stem Cell And Regenerative Therapy Market 2019-2024 Chain Analysis, Upstream Raw Materials Sourcing and Downstream Buyers - Feed Road

Scientists Create Human ‘Body-On-A-Chip’ Featuring Tiny Replica Organs In The Lab – IFLScience

Researchers have created what they say is the world's most sophisticated lab model of the human body: a system of mini-organs made fromreal human cells and stem cells.

While it may sound like attempts to make a miniature Frankensteins monster in a petri dish, the researchers are actually hoping to create an entire lab model of miniaturized human organs that could become invaluable for drug testing and biomedical research.

Reporting in the journal Biofabrication, scientists from Wake Forest Institute for Regenerative Medicine (WFIRM) in North Carolina created a human organ tissue system that features a miniature heart-like organ that beats about 60 times a minute, a lung that breathes the air from the surrounding environment, and a liver that breaks down toxic compounds, as well as testicles and a colon.

Although just one-millionth the size of a full-sized adult human organ, these body-on-a-chip" systems are remarkably detailed, complete with their own blood vessel cells, immune system cells, and connective tissue cells. It also contains a microfluidic circuit thats able to circulate a drug throughout the system between organs, just like how a cardiovascular system pumps molecules through the human body in the blood.

Creating microscopic human organs for drug testing was a logical extension of the work we have accomplished in building human-scale organs, said study co-author Thomas Shupe of WFIRM in astatement. Many of the same technologies we have developed at the human-scale level, like including a very natural environment for the cells to live in, also produced excellent results when brought down to the microscopic level.

Don't worry, this isn't scientists creating a tiny "artificial human" the system is barely more thana load of blobs in a petri dish, not a conscious organism.

Organoids are invaluable tools for scientists looking to understand the human body. In one of the most incredible breakthroughs, researchers recently observed brain organoids that began to show signs of brain waves similar to those of preterm infants. Its hoped this kind of research could be used to understand how brain cells develop into the intensely complex organ currently sitting in your head.

They are also extremely useful for testing new pharmaceutical drugs because they react, in theory, just as a real human organ would. Plus, they are safe and relatively low-cost. The newly developed miniature organ model has already been used for a number of tests to assessthetoxicity of some drugs. In some instances, the organ model managed to show adrug might be dangerous or have some undesired effect, thereby potentially preventing harm to humans.

Link:
Scientists Create Human 'Body-On-A-Chip' Featuring Tiny Replica Organs In The Lab - IFLScience

Adult Stem Cells

By: Ian Murnaghan BSc (hons), MSc - Updated: 21 Feb 2019| *Discuss

Although stem cells have defining characteristics, they do have different sources. Adult stem cells, also called somatic stem cells, possess the same basic characteristics of all stem cells. An adult stem cell is an unspecialised cell that is capable of:

Another goal is to develop insulin-producing cells for diabetes. With heart attacks causing enormous morbidity and mortality each year, it is also hoped that adult stem cells can repair damage to the heart.

The use of adult stem cells is more widely accepted, particularly by the public, because it does not require destruction of an embryo as with embryonic stem cells. Adult stem cells also don't have the same immunological challenges as embryonic stem cells because they are harvested from the patient. This means that a person's body is less likely to reject the stem cells because they are compatible with that person's unique physiological makeup.

Overall, adult stem cells don't pose the same ethical concerns and controversy in comparison with embryonic stem cells, but their practical challenges are numerous. As scientists continue to seek ways to effectively harvest adult stem cells, the public can await new treatments for some of the more serious and common diseases.

You might also like...

Share Your Story, Join the Discussion or Seek Advice..

non - 21-Feb-19 @ 11:47 PM

Kaboom - 22-Mar-17 @ 9:13 PM

Sara - 28-Feb-16 @ 9:09 PM

Ian - 28-Sep-14 @ 3:43 PM

Ken - 4-Jun-14 @ 11:16 PM

sfevans - 4-Jun-14 @ 2:59 AM

mojo - 30-Mar-14 @ 5:47 AM

El Magico - 22-May-12 @ 9:13 PM

jossy - 2-Mar-12 @ 8:56 PM

Title:

(never shown)

Read this article:
Adult Stem Cells

Australia’s Mesoblast plans to evaluate its stem cell therapy in patients infected with COVID-19 – BioWorld Online

PERTH, Australia Australian stem cell therapy company Mesoblast Ltd. plans to evaluate its allogeneic mesenchymal stem cell (MSC) candidate, remestemcel-L, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the U.S., Australia, China and Europe.

The company is in active discussions with various governments, regulatory authorities, medical institutions and pharmaceutical companies to implement these activities.

What people are dying of is acute respiratory distress syndrome, which is the bodys immune response to the virus in the lungs, and the immune system goes haywire, and in its battle with the virus it overreacts and causes severe damage to the lungs, Mesoblast CEO Silviu Itescu told BioWorld.

Were going to be evaluating whether an injection of our cells intravenously can tone down the immune system just enough so it gets rid of the virus but doesnt destroy your lungs at the same time.

Recently published results from an investigator-initiated clinical study conducted in China reported that allogeneic MSCs cured or significantly improved functional outcomes in all seven treated patients with severe COVID-19 pneumonia.

We have now looked at our own data in lung disease in adults where half the patients had the same kind of inflammation in the lungs as you get with coronavirus, and our cells significantly reduced the inflammation and significantly improved lung function, Itescu said, noting that he is awaiting emergency use authorization to treat patients under a clinical trial protocol.

In a post-hoc analyses of a 60-patient randomized controlled study in chronic obstructive pulmonary disease (COPD), remestemcel-L infusions were well-tolerated, significantly reduced inflammatory biomarkers, and significantly improved pulmonary function in those patients with elevated inflammatory biomarkers.

Since the same inflammatory biomarkers are also elevated in COVID-19, those data suggest that remestemcel-L could be useful in the treatment of patients with ARDS due to COVID-19. The COPD study results have been submitted for presentation at an international conference, with full results to be submitted for publication shortly.

Mortality in COVID-19-infected patients with the inflammatory lung condition is reported to approach 50% and is associated with older age, co-morbidities such as diabetes, higher disease severity, and elevated markers of inflammation.

Current therapeutic interventions do not appear to be improving in-hospital survival, and remestemcel-L has potential for use in the treatment of ARDS, which is the principal cause of death in COVID-19 infection.

Itescu said he didnt know of any other stem cell companies that were doing this. He said that other companies could try the approach from a research perspective but that Mesoblast has all the patents locked down.

The companys intellectual property portfolio encompasses more than 1,000 patents or patent applications in all major markets and includes the use of MSCs obtained from any source for patients with ARDS, and for inflammatory lung disease due to coronavirus (COVID-19), influenza and other viruses.

Remestemcel-L is being studied in numerous clinical trials across several inflammatory conditions, including in elderly patients with lung disease and adults and children with steroid-refractory acute graft-vs.-host disease (aGVHD).

Mesoblasts stem cell therapy is currently being reviewed by the FDA for potential approval in the treatment of children with steroid-refractory aGVHD. The company submitted the final module of a rolling BLA in January.

Remestemcel-L is being developed for rare pediatric and adult inflammatory conditions. It is an investigational therapy comprising culture-expanded MSCs derived from the bone marrow of an unrelated donor and is administered in a series of intravenous infusions.

The stem cell therapy is believed to have immunomodulatory properties to counteract the inflammatory processes that are implicated in several diseases by down-regulating the production of pro-inflammatory cytokines, increasing production of anti-inflammatory cytokines, and enabling recruitment of naturally occurring anti-inflammatory cells to involved tissues, according to Mesoblast.

See the article here:
Australia's Mesoblast plans to evaluate its stem cell therapy in patients infected with COVID-19 - BioWorld Online

Astronauts growing new organs on International Space Station – The Independent

Astronauts are growing the beginnings of new organs on board the International Space Station.

The experiment is an attempt to grow human tissue by sending adult human stem cells into space, and allowing them to grow in space.

Eventually, it is hoped, the stem cells will develop into bone, cartilage and other organs. If that is successful, the discoveries could be used to try and grow organs for transplant, the scientists involved say.

Sharing the full story, not just the headlines

The experiment uses weightlessness as a tool, according to Cara Thiel, one of the two researchers from the University of Zurich who are conducting the research. The lack of gravity on board the International Space Station will be used to encourage the stem cells to grow into tissue in three dimensions, rather than the single-layerstructures that form on Earth.

It is being conducted by the astronauts on board the International Space Station using a mobile mini-laboratory that was sent on a SpaceX rocket last week. The experiment will last for a month, during which scientists will watch to see how the stem cells grow.

Mystic Mountain, a pillar of gas and dust standing at three-light-years tall, bursting with jets of gas flom fledgling stars buried within, was captured by Nasa's Hubble Space Telelscope in February 2010

Nasa/ESA/STScI

The first ever selfie taken on an alien planet, captured by Nasa's Curiosity Rover in the early days of its mission to explore Mars in 2012

Nasa/JPL-Caltech/MSSS

Death of a star: This image from Nasa's Chandra X-ray telescope shows the supernova of Tycho, a star in our Milky Way galaxy

Nasa

Arrokoth, the most distant object ever explored, pictured here on 1 January 2019 by a camera on Nasa's New Horizons spaceraft at a distance of 4.1 billion miles from Earth

Getty

An image of the Large Magellanic Cloud galaxy seen in infrared light by the Herschel Space Observatory in January 2012. Regions of space such as this are where new stars are born from a mixture of elements and cosmic dust

Nasa

The first ever image of a black hole, captured by the Event Horizon telescope, as part of a global collaboration involving Nasa, and released on 10 April 2019. The image reveals the black hole at the centre of Messier 87, a massive galaxy in the nearby Virgo galaxy cluster. This black hole resides about 54 million light-years from Earth

Getty

Pluto, as pictured by Nasa's New Horizons spacecraft as it flew over the dwarf planet for the first time ever in July 2015

Nasa/APL/SwRI

A coronal mass ejection as seen by the Chandra Observatory in 2019. This is the first time that Chandra has detected this phenomenon from a star other than the Sun

Nasa

Dark, narrow, 100 meter-long streaks running downhill on the surface Mars were believed to be evidence of contemporary flowing water. It has since been suggested that they may instead be formed by flowing sand

Nasa/JPL/University of Arizona

Morning Aurora: Nasa astronaut Scott Kelly captured this photograph of the green lights of the aurora from the International Space Station in October 2015

Nasa/Scott Kelly

Mystic Mountain, a pillar of gas and dust standing at three-light-years tall, bursting with jets of gas flom fledgling stars buried within, was captured by Nasa's Hubble Space Telelscope in February 2010

Nasa/ESA/STScI

The first ever selfie taken on an alien planet, captured by Nasa's Curiosity Rover in the early days of its mission to explore Mars in 2012

Nasa/JPL-Caltech/MSSS

Death of a star: This image from Nasa's Chandra X-ray telescope shows the supernova of Tycho, a star in our Milky Way galaxy

Nasa

Arrokoth, the most distant object ever explored, pictured here on 1 January 2019 by a camera on Nasa's New Horizons spaceraft at a distance of 4.1 billion miles from Earth

Getty

An image of the Large Magellanic Cloud galaxy seen in infrared light by the Herschel Space Observatory in January 2012. Regions of space such as this are where new stars are born from a mixture of elements and cosmic dust

Nasa

The first ever image of a black hole, captured by the Event Horizon telescope, as part of a global collaboration involving Nasa, and released on 10 April 2019. The image reveals the black hole at the centre of Messier 87, a massive galaxy in the nearby Virgo galaxy cluster. This black hole resides about 54 million light-years from Earth

Getty

Pluto, as pictured by Nasa's New Horizons spacecraft as it flew over the dwarf planet for the first time ever in July 2015

Nasa/APL/SwRI

A coronal mass ejection as seen by the Chandra Observatory in 2019. This is the first time that Chandra has detected this phenomenon from a star other than the Sun

Nasa

Dark, narrow, 100 meter-long streaks running downhill on the surface Mars were believed to be evidence of contemporary flowing water. It has since been suggested that they may instead be formed by flowing sand

Nasa/JPL/University of Arizona

Morning Aurora: Nasa astronaut Scott Kelly captured this photograph of the green lights of the aurora from the International Space Station in October 2015

Nasa/Scott Kelly

If it is successful, they hope to switch from a small laboratory to bigger production. From there, they could use the process to generate tissue for transplants by taking cells from patients, or generating organ-like materialthat could be used to test drugs, either ensuring that it works for a specific patients or reducing the number of animals used in experiments.

On Earth, tissue grows in monolayer cultures: generating flat, 2D tissue. But investigations both in space and Earth suggest that in microgravity, cells exhibit spatially unrestricted growth and assemble into complex 3D aggregates, saidOliver Ullrich, who is also leading the research.

Previous research has involved simulated ad real experiments, mostly using tumour cells, and placing real human stem cells into microgravity simulators. But for the next stage of the research there is no alternative to the ISS, he says, because 3D tissue formation of this kind requires several days or even weeks in microgravity.

After the month-long experiment, the scientists will get the samples back and expect to see successful formation oforganoids smaller, more simple versions of organs inside the test tubes. The test tubes were launched with stem cells and are expected to return to Earth with organ-like tissue structures inside, said Professor Ullrich.

Scientists are still not sure why the conditions of the International Space Station lead to the assembly of complex 3D tissue structures. Professor Ullrich and other scientists are still continuing to research how the gravitational force and the molecular machinery in the cell interact to create new and different kinds of tissue on Earth and in space.

See original here:
Astronauts growing new organs on International Space Station - The Independent

How to build a body from scratch, Altered Carbon-style – SYFY WIRE

The world of Netflix's Altered Carbon is one where consciousness is no longer tethered to the physical body. It can be, and regularly is, uploaded into "cortical stacks," which are implanted at the base of the neck. In the event of death, a persons consciousness can be reloaded into a new body, known as a "sleeve." For those less fortunate, like protagonist Takeshi Kovacs, that might mean receiving a body thats not your own. In one particularly existential example from the series first episode, it might even mean a young child being uploaded into the body of an adult.

For those with means, however, the mind can be placed into a swiftly made, identical clone, allowing them to return to their lives with little interruption. We've covered what it might take to create a digital copy of a persons mind before (spoiler: it wouldnt be easy), but Altered Carbon's techno-immortality requires a second piece: the swift creation of replacement bodies.

One of the major hurdles that has kept real-world cloning from being the game changer everyone suspected it might be after the birth of Dolly, the first successfully cloned mammal, is the relatively slow development of human bodies. If you wanted to clone a 50-year-old human and get them back to the same stage of development, it would take you 50 years. That's a little too slow to make use of in the same way science fiction does.

We don't have the means to artificially age a body at a rapid pace, but what if we were able to shortcut these limitations to put it plainly, what would it take to build an adult body from scratch?

BONES

If you want to build a person from scratch, you must first make the universe. Carl Sagan said something like that, I think. Just after that, though, youll need a skeleton. Without bones, youll be left with little more than a Cronenbergian nightmare, cool in its own way, but not what were shooting for.

Today, if you have trouble with your bones, your options are limited. The first option, and in most cases the best one, is to let the bone heal itself. Your body is pretty resilient and capable of repairing most day-to-day injuries, even the ones accompanied by a sickening crack. If the injury is really bad, things get a little more medieval. Surgeons might use a series of metal plates and screws to hold your bones in place and give them time for your bodys healing processes to do their work. But those solutions only work for relatively minor injuries where the bone tissue is at least moderately intact.

When it comes to bone replacements, things are a little tougher.

Again, we can return to metal. Like the Wolverine, you might have part of your skeleton replaced or covered over with metal. This might be sufficient in specific cases, but it all feels a little crude.

Ramille Shah, Ph.D., headed a team out of Northwestern's McCormick School of Engineering to create a new material capable of instigating rapid bone regeneration. The team used 3D printers (the invention that never stops giving) and a mixture of 90 percent hydroxyapatite, a natural element of human bones, and 10 percent medical polymer to build bone constructs.

The result is a bit of artificial bone modeled in whatever shape the patient needs. It is porous, allowing for blood vessels and other tissues to easily integrate. The elastibone (perhaps the worst superhero name, trademark pending) stimulates bone regeneration and degrades over time. The intent is for the artificial structure to dissipate, leaving actual bone in its place. A technology like this would go a long way to repairing complex bone defects in all manner of patients, but is particularly promising in pediatrics, where the patients are still growing.

But, in order to truly build a bone from scratch, well need something even better. Thats where Nina Tandon and EpiBone come in.

This technology would work by taking a sample of fatty tissue, something readily available if your plan is to build a copy of an existing person, and use it to extract stem cells. Those cells would then be applied to a 3D printed scaffold of a cows bone which has been scrubbed of all its living cells. Those undifferentiated stem cells would then be placed into a bioreactor (something which sounds made up but is very real) and coaxed into growing into a fully formed bone in just a few weeks. Given enough bioreactors, and enough cows (pour one out for our fallen bovine brethren) you could feasibly grow an entire skeleton in the time it takes for you to finally fold the laundry thats been sitting in the corner of your room.

Now that youve got a skeleton, youre going to need some

ORGANS

For a long time, there weren't many ways to get a new organ if you needed one. The most commonly used method (we hope) was to get your name on a list and wait for a donor. The unfortunate reality of organ donation is that there are more people who need organs than there are organs available. Even when an organ does become available, the odds are against you that theyll match your bodys preferences, and even if you get a match, theres always the threat of rejection.

Organ transplants are a veritable miracle procedure and, while we sometimes take them for granted, they are evidence of our living in truly wizardly times in medical science. But science is never content with the status quo and humanity is forever wondering if we can further laugh in the face of nature. The preferred solution would be to develop a way to craft bespoke organs, made from the recipients' own cells.

Growing cells in a petri dish is old hat. Weve been doing that for longer than many of us have been alive. The trouble is, you can take a heart cell and induce it to multiply in a dish, but all you end up with is a dish-shaped collection of heart cells. That might be good for studying cellular biology, not so good for pumping blood through a person.

A collection of cells does not an organ make. You need something more a scaffold. Each of your organs is a complex collection of various cell types clinging to a protein structure. You can think of that structure as the framing around which the rest of a house is built. Without it, you've got little more than some insulation and drywall tossed into a haphazard stack. You need that scaffold.

There are hopes that one day well be able to build them via (drum roll please) 3D printing, but were not there yet. The level of minute detail involved is beyond our current ability. So, we have to borrow from nature.

Scientists are able to take an existing organ and strip it of its surface cells by pumping detergent through it (good for removing pesky stains and unwanted biological material). Whats left is a ghostly protein structure ready for seeding.

All that's left is to take tissue samples from the recipient and seed them onto the structure, pop it into one of those handy bioreactors, and let the cells get to work. Eventually, youll end up with an organ made of the patients own tissues. Current tests are pretty impressive, but were still a ways off from having a functioning process. The number of different tissue types involved in complex organs is a barrier and the complexity of small structures like circulatory vessels is another. Still, the technology is promising and would not only allow us to build any and all organs in record time, it would solve the organ transplant shortage and save countless lives.

So, now youve got a rigid skeleton filled with juicy oozing organs. Your neighbors are starting to wonder about the smell coming from your garage and youre grateful this abominable creature is not yet sentient because it would very likely go running for the hills. At least it would if it had

MUSCLES

Look, we all know its been a while since youve been to the gym. You bought a membership for the new year and you went a few times. You really meant well but life happened and, somehow, it all got away from you. We get it. It happens to the best of us.

While you might not have the muscle mass you wish you had, you still have quite a lot. The average persons body is comprised of somewhere between 35 and 40 percent muscle, give or take. Thats a lot. Even after all of your efforts with bioreactors, youve only managed to make 60 percent of a person. Its nothing to be scoffed at, but you arent done yet.

In order to complete next steps, youre going to need more tissue samples and a few friends from Duke University.

Using human cells that were no longer stem cells but not yet muscle cells, Nenad Bursac and Lauran Madden, an associate professor of biomedical engineering and a postdoctoral researcher, respectively, were able to successfully create functioning muscle tissues in a lab.

They grew the tissue samples and, using a 3D scaffold and a nutritive gel, ended up with working muscle fibers. These bundles of muscle fibers included receptors capable of taking in external stimuli and contracted when acted on by electricity.

For their part, the intent is not to build novel muscular structures, but to test the efficacy of drugs to treat diseases. According to Bursac, drug tests in the laboratory matched results seen in living patients. Those patients with muscular ailments could provide a tissue sample, that sample could then be grown into fiber bundles and used to test various drug treatments, ex vivo, to find a workable treatment without all the trial and error usually required.

Thanks to Bursac and the team at Duke, youve now built almost all of Takeshi Kovacs. Hes twitching and moving around on the table. He might be screaming a little, thanks to those vat-grown lungs and hes still oozing a bit. Most of all, hes embarrassed by his nakedness. A lots changed in the intervening centuries, but not the need for

SKIN

Youve got your terrible Frankensteinian gift all put together, all thats left is the wrapping. Here, too, is an area were moderately familiar with. When a patient loses skin through injury, a graft can be taken from elsewhere and used to replace the damaged tissue. It gets the job done, some skin is better than no skin of course, but theres still room for improvement.

More recently, bioengineers have had some success in growing sheets of epithelial tissue for implantation but they lacked oil and sweat glands. Again, close, but not quite. Until

A study undertaken at the RIKEN Center for Developmental Biology, led by Takashi Tsuji took cells from the gums of mice and used chemicals to revert them to a stem-cell-like state. The cells were used to grow complex skin tissues.

Once the tissues were ready, they were transplanted onto living mice and were found to develop normally. Not only did those tissues function as a protective barrier, the primary function of skin, but they also succeeded in developing hair follicles and sweat glands. Even more importantly, they successfully integrated with surrounding tissue systems like muscle groups and nerves.

There are, of course, other tissue types weve not covered, each of them important to the successful functioning of a body, but if these emerging technologies are any indication, were well on our way in those areas as well.

So, youve done it. Youve made a full-grown human from scratch in months rather than decades. All thats left is to upload a mind and youre well on your way to cyberpunk chicanery. Go forth, Kovacs, we're rooting for you. And dont mess up this body, please. It was really hard to make. Thanks.

Read the original post:
How to build a body from scratch, Altered Carbon-style - SYFY WIRE

The Inside Scoop on Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) – MicroCap Daily

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is an exciting little biotech that has managed to attract legions of shareholders who continue to accumulate. The stock does have a history of big moves up recently seeing another significant pop.

There is a lot to get excited about on NWBO, the Company is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs.

Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) is a clinical stage biotechnology company focused on the development of personalized immunotherapy for a broad range of solid tumor cancers. The company has over 190 issued patents and more than 65 pending patent applications worldwide, grouped into 12 patent families. The Company is led by Linda Powers, a successful entrepreneur who worked for many years in corporate finance and restructurings, mergers and acquisitions, joint ventures and intellectual property licensing. Ms. Powers has served as the Chairman of NW Bio since 2007, and as CEO since 2011. NWBO platform technology is DCVax, which uses activated dendritic cells to mobilize a patients own immune system to attack their cancer.

Northwest lead product is DCVax-L for Glioblastoma multiforme (GBM), the most lethal form of primary brain cancer. The Company has completed two Phase I/II trials and are now well under way with a large Phase III trial, as described below. Northwest is currently conducting a 348-patient double blind, randomized, placebo controlled Phase III clinical trial with DCVax-L for newly diagnosed GBM. The primary endpoint of the trial is Progression Free Survival, meaning the length of time that a patient continues without disease progression (i.e., recurrence of the tumor). Secondary endpoints include overall survival and other measures. The trial is under way at 51 sites (medical centers) across the US. The sites and the eligibility criteria are listed in the profile of the trial at ClinicalTrials.gov. The trial is also under way in Europe. The lead site is Kings College Hospital in London. Approximately 30 trial sites are also in varying stages of preparation in the U.K. and Germany.

DCVax Direct offers a potential new treatment option for the wide range of clinical situations in which patients tumors are considered inoperable because the patient has multiple tumors, or their tumor cannot be completely removed, or the surgery would cause undue damage to the patient and impair their quality of life. DCVax-Direct is administered by direct injection into a patients tumors. It can be injected into any number of tumors, enabling patients with locally advanced disease or with metastases to be treated. DCVax-Direct can also be injected into tumors in virtually any location in the body: not only tissues at or near the surface of the body but also, with ultra-sound guidance, into interior tissues. Northwest is currently conducting a 60-patient Phase I/II trial of DCVax-Direct for all types of inoperable solid tumors. The trial is under way at MD Anderson in Houston, TX and MD Anderson in Orlando, FL, with additional sites in varying stages of preparation. The Phase I stage of the trial involves dose escalation, testing 3 different dose levels of DCVax-Direct, and confirmation of the optimal dose.

To Find out the inside Scoop on NWBO Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DCVax-Prostate is designed specifically for late stage, hormone independent prostate cancer. Such cancer involves the spread of micro-metastases beyond the prostate tissue. In most patients, there is no focal tumor which can be surgically removed and used to make lysate, or into which dendritic cells can be directly injected. Instead, the cancer cells are diffuse. We have developed a DCVax product line using a particular proprietary antigen PSMA (Prostate Specific Membrane Antigen) which is found on essentially all late stage (hormone independent) prostate cancer. The PSMA is produced through recombinant manufacturing methods, and is then combined with the fresh, personalized dendritic cells to make DCVax-Prostate.

Northwest is led by Linda Powers, her linkedin page describes her as: Ms. Powers served as Chairman of NW Bio for the last 4 years, and brings more than 25 years experience in corporate transactions and operations, including more than a decade specializing in building biotech companies through Toucan Capital. Ms. Powers is particularly well known for her experience in building biotech companies that are developing cell therapies, including both immune cell therapies (such as NWBios DCVax) and adult stem cell therapies. Such products consisting of living human cells require fundamentally different manufacturing, storage, distribution and handling than do pharmaceutical drugs (pills in bottles). Such living cell products also involve different clinical and regulatory requirements, and different business and cost/pricing models, than traditional drugs. The cell therapy companies which Ms. Powers has been involved in building over the last decade, both in the US and abroad (in Asia, Europe and Israel), are at the forefront of clinical trials and early commercialization. Ms. Powers has served for years on a number of related boards, including the M2Gen Board of the Moffitt Cancer Center, the Board of the Trudeau Institute (a world leader in immunology research) and others. As Chairman of NW Bio, she has brought her lengthy experience to bear in helping to shape NW Bios overall strategy and programs. As CEO, she will now undertake operational responsibilities in addition to continuing her duties as Chairman.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $129 million market valuation NWBO has $1.9 million in the treasury, manageable debt and fast growing sales reporting $593k in revenues for the 3 months ended September 30, 2019. NWBO is an exciting story developing in small caps; this little biotech is sitting on drugs in development that could potentially turn the multi-billion dollar drug-resistant cancers market upside down. NW Bio lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. The stock has a significant shareholder base that continues to bid this one higher. We will be updating on NWBO when more details emerge so make sure you are subscribed to Microcapdaily so you know whats going on with NWBO.

Disclosure: we hold no position in NWBO either long or short and we have not been compensated for this article.

Visit link:
The Inside Scoop on Northwest Biotherapeutics, Inc (OTCMKTS: NWBO) - MicroCap Daily

Adult Stem Cells: Market 2020 New Innovative Solutions to Boost Global Growth with New Technology, Key Business Strategies, Trend and Forecasts 2024 -…

The Global Adult Stem Cells Market Report Provides A Detailed Analysis of The Current Dynamics of The Market with An Extensive Focus on Secondary Research. It Also Studies the Current Situation of The Market Estimate, Share, Demand, Development Patterns, And Forecast in The Coming Years. The Report Likewise Offers A Total Adult Stem Cells Analysis of Things to Come Patterns and Improvements. It Likewise Examines at The Job of The Main Market Players Engaged with The Business Including Their Adult Stem Cells Corporate Review, Financial Summary and SWOT Analysis.

This Adult Stem Cells Market Report That Is Imagines That the Length of This Market Will Develop during The Time System While the Compound Annual Growth Rate (CAGR) Development. The Adult Stem Cells Business Report Point Would Be the Economic Situations and Relating Orders and Takes the Market Players in Driving Fields Over the World.

GlobalstemJuventas Therapeutics Inc.Epistem Ltd.Hybrid Organ GmbhCellerix SaMesoblast Ltd.Intellicell Biosciences Inc.NeuralstemCelyadCapricor Inc.ClontechCellerant Therapeutics Inc.Cellular Dynamics InternationalBiotime Inc.Beike Biotechnology Co. Ltd.Brainstorm Cell Therapeutics Inc.NeurogenerationInternational Stem Cell Corp.Gamida Cell Ltd.Caladrius Biosciences Inc.Cytori Therapeutics Inc.

Most important types of Adult Stem Cells products covered in this report are:Epithelial stem cellsHematopoietic stem cells

Most widely used downstream fields of Adult Stem Cells market covered in this report are:Neurodegenerative diseasesHeart diseaseBone diseaseOthers

Which prime data figures are included in the Adult Stem Cells market report?

What are the crucial aspects incorporated in the Adult Stem Cells market report?

Who all can be benefitted out of this Adult Stem Cells market report?

Research Goals:

The Report on Global Adult Stem Cells Market Studies the Strategy Pattern Adopted by Prominent International Players. Additionally, The Report Also Evaluates the Market Size in Terms of Revenue (USD MN) For the Forecast Period. All Data and Figures Involving Percentage Shares Splits, And Breakdowns Are Determined Using Secondary Sources and Verified Through Primary Sources.

Contact Us:Web: http://www.qurateresearch.comE-mail: [emailprotected]Ph: US +13393375221, IN +919881074592

Original post:
Adult Stem Cells: Market 2020 New Innovative Solutions to Boost Global Growth with New Technology, Key Business Strategies, Trend and Forecasts 2024 -...

Review Finds The Effects Of Obesity On The Body Mirror Those Of Aging – IFLScience

Obesity is a widespread health concern affecting around 1.9 billion adults and 380 million children across the globe, with reports from the World Health Organization (WHO) saying that more people are now dying as a result of being overweight than underweight. Obesity has long been known to cause devastation to vital organs and vessels, but new research published in the journal Obesity Reviews highlights how the changes it causes both to our bodies and on a cellular level reflect those of aging.

Obesity increases your risk of developing diseases thatcan dramatically alter your quality of life or even prove fatal. It can cause compromised genomes that increase your risk of cancer and a weakened immune system, making you sicker more often. It also leads to decreased cognition and increases your chances of developing Alzheimer's disease and cardiovascular disease, alongside a host of other illnesses.

The team reviewed over 200 papers looking at the effects of obesity on one'shealth andcells. Weve known for a while that obesity is linked to premature death, but the review also noted the link between obesity and cell death (apoptosis) and the maintenance of healthy cells (autophagy) two processes thatare known to impact physical aging.

"We are trying to comprehensively make the argument that obesity parallels aging," said lead researcher Sylvia Santosa, a Tier II Canada Research Chair in Clinical Nutrition, in a statement. "Indeed, the mechanisms by which the comorbidities of obesity and aging develop are very similar."

One study on various organs of mice including the heart, liver, and kidneys found that apoptosis was increased in clinically obese subjects. Meanwhile, another paper observed that autophagy, which is the bodys way of clearing out unhealthy cells, was negatively impacted, a consequence thatis strongly linked to the emergence of diabetes, Alzheimers, and cardiovascular disease.

Researchers on the review also found obesity can impact our ability to fight off illness as it speeds up the aging of the immune system by targeting different immune cells. These changes not only negatively impacted the bodys ability to fight sickness but also couldnt be reversed by weight loss at a later time. This means obese individuals are at greater risk of picking up bugs like influenza, which are already known to cause more severe symptoms in significantly overweight individuals.

As well as physical changes to our health and cells, aging can be observed at the genetic level as alterations impact the quality of our chromosomes, making them more likely to code for errors and dysfunctional cells. One such example was the shortening of telomeres protective caps thatwere observed to be 25 percent shorter in obese participants when compared to those of a healthy weight.

Scaling up, the review also found that more tangible issues such as cognitive decline, reduced mobility, and increased hypertension and stress all age-related problems associated with later life were seen in obese participants.

The extensive review came about in response to the rising trend of obese children and young adults developing adult-onset conditions such as high cholesterol, diabetes, and hypertension. In a statement, Santosa said, "I ask people to list as many comorbidities of obesity as they can. Then I ask how many of those comorbidities are associated with aging. Most people will say all of them. I'm hoping that these observations will focus our approach to understanding obesity a little more, and at the same time allow us to think of obesity in different ways.

Find out how human stem cells could hold the key to curing diabetes.

Read more:
Review Finds The Effects Of Obesity On The Body Mirror Those Of Aging - IFLScience

Stem Cells Market is expected to reach US$270.5 billion by 2025, TMR – BioSpace

The global stem cells market is predicted to witness players seeking funds from international organizations for developing new therapies. With a view to cement their position in the market, players could take to the adoption of partnerships and collaborations with pharmas. This could also help them to expand their product portfolios. While these factors are expected to enhance market growth, there could be a few others helping with strong demand for stem cells.

Transparency Market Research (TMR) foresees the global stem cells market to earn a US$270.5 bn by the completion of 2025 while registering a 13.8% CAGR for the forecast tenure 2017-2025. In a research led by University of Singapores (NUS) Professor G.V. Shivashankar and the FIRC Institute of Molecular Oncology (IFOM), it has been found that mature cells can be confined to reprogram them into re-deployable stem cells. Interestingly, this could be achieved without direct genetic modification.

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough, request for custom research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=132

Induced Pluripotent Stem Cells as Emerging Segment of Market

There are various types of products available in the global stem cells market: induced pluripotent, human embryonic, and adult stem cells. Among these, the market could find adult stem cells collecting a larger share in the coming years. Their demand could increase due to their potential to multiply into trillions of specialized cells capable of repairing tissue damage and lowering the risk of rejection.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=132

North America Banks on Massive Investments to Lead Market

On the regional front, the global stem cells market is prognosticated to find North America taking a leading position in the near future. By the end of the forecast period, the region could earn US$167.3 bn. The following factors are anticipated to augur well for the regional market.

North America could be trailed by Europe during the course of the forecast period. Medical tourism in European countries such as Germany could push the growth of the market in the region. Germany welcomes patients from the U.S., Canada, and even other countries. On the other hand Asia Pacific is expected to grow at a faster CAGR of 14.6%.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Purchase this Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=132&ltype=S

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY - 12207United StatesUSA - Canada Toll Free: 866-552-3453Email: sales@transparencymarketresearch.comWebsite: https://www.transparencymarketresearch.com/

Follow this link:
Stem Cells Market is expected to reach US$270.5 billion by 2025, TMR - BioSpace